Objective: Plasma interleukin-1 beta may influence sepsis mortality, yet recombinant human interleukin-1 receptor antagonist did not reduce mortality in randomized trials. We tested for heterogeneity in the treatment effect of recombinant human interleukin-1 receptor antagonist by baseline plasma interleukin-1 beta or interleukin-1 receptor antagonist concentration. Design: Retrospective subgroup analysis of randomized controlled trial. Setting: Multicenter North American and European clinical trial. Patients: Five hundred twenty-nine subjects with sepsis and hypotension or hypoperfusion, representing 59% of the original trial population. Interventions: Random assignment of placebo or recombinant human interleukin-1 receptor antagonist × 72 hours. Measurements and Main Results: We measured prerandomization plasma interleukin-1 beta and interleukin-1 receptor antagonist and tested for statistical interaction between recombinant human interleukin-1 receptor antagonist treatment and baseline plasma interleukin-1 receptor antagonist or interleukin-1 beta concentration on 28-day mortality. There was significant heterogeneity in the effect of recombinant human interleukin-1 receptor antagonist treatment by plasma interleukin-1 receptor antagonist concentration whether plasma interleukin-1 receptor antagonist was divided into deciles (interaction p = 0.046) or dichotomized (interaction p = 0.028). Interaction remained present across different predicted mortality levels. Among subjects with baseline plasma interleukin-1 receptor antagonist above 2,071 pg/mL (n = 283), recombinant human interleukin-1 receptor antagonist therapy reduced adjusted mortality from 45.4% to 34.3% (adjusted risk difference, -0.12; 95% CI, -0.23 to -0.01), p = 0.044. Mortality in subjects with plasma interleukin-1 receptor antagonist below 2,071 pg/mL was not reduced by recombinant human interleukin-1 receptor antagonist (adjusted risk difference, +0.07; 95% CI, -0.04 to +0.17), p = 0.230. Interaction between plasma interleukin-1 beta concentration and recombinant human interleukin-1 receptor antagonist treatment was not statistically significant.
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For information regarding this article, E-mail: nuala.meyer@uphs.upenn.edu Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration* S epsis and septic shock are common causes of death in ICUs and are estimated to affect 19 million people annually worldwide (1) . The mortality rate for sepsis exceeds 25% (2) . Numerous pharmacologic agents have failed to decrease sepsis mortality, leading many to believe that a precision medicine option may be a more effective approach (3). Ideally, a precision medicine approach would rely on a predictive enrichment tool such as a clinical risk factor, plasma biomarker, or gene expression pattern to identify patients most likely to benefit from the therapy in question (4, 5) . This approach has been highly successful in cancer therapy, leading to widespread appreciation that therapies may act differently among distinct endotypes of patients (6) (7) (8) .
One sepsis therapy that showed promise was recombinant interleukin-1 receptor antagonist (rhIL1RA), a synthetic form of the naturally occurring anti-inflammatory cytokine IL1RA. IL1RA competes with interleukin-1 alpha and beta (IL1α, IL1β) to bind the interleukin-1 receptor without triggering receptor signaling (9, 10). There was enthusiasm for rhIL1RA in sepsis because IL1β incites permeability and activates inflammatory cytokine production in vitro (11) (12) (13) , and in animals, IL1RA reverses IL1β-mediated febrile vasodilatory shock (14) (15) (16) . Our group has shown improved sepsis survival associated with a high-functioning variant in the gene encoding IL1RA and, in a Mendelian randomization analysis, that genetically determined variation in plasma IL1β associates with sepsis mortality (17, 18) , potential evidence that plasma IL1β may have a causal role in sepsis outcomes. Three randomized placebo controlled trials of rhIL1RA in sepsis were conducted in the 1990s (19) (20) (21) . Although these trials demonstrated a potential effect for reduced mortality, the effect was small (2-5% absolute risk reduction), not statistically significant, and predictors of response were lacking.
We undertook the current study to test for potential heterogeneity in rhIL1RA treatment effect by plasma IL1RA or IL1β concentration. We hypothesized that treatment may interact with baseline plasma status to influence mortality, and that patients with an activated IL-1 axis would benefit from rhIL1RA.
MATERIALS AND METHODS
Patients enrolled in the phase III rhIL1RA Sepsis Syndrome Study, a multicenter trial enrolling during 1992, were eligible for inclusion in this study if baseline plasma was available (20) .
For the original trial, eligible adult patients had a strongly suspected infection, systemic inflammatory response syndrome criteria, and hypotension or hypoperfusion attributed to sepsis within 24 hours of enrollment (22) . Major exclusion criteria included pregnancy, obesity, prior transplant, immunosuppression, or morbid status. At each participating center, the Institutional Review Board or Ethical Review Committee approved the trial, and informed consent for participation was obtained from patient or family before study participation (20) . Of 893 subjects in the original trial, banked plasma drawn prerandomization and clinical data were available for 529 (59%). Patients were randomized 1:1:1 in a blinded fashion to bolus rhIL1RA 100 mg and 72-hour infusion of 1.0 mg/ kg/hr rhIL1RA or 2.0 mg/kg/hr rhIL1RA or to bolus placebo (vehicle) and 72-hour infusion of placebo. Antibiotic, fluid, and ventilator care were managed by the treating physician. The primary outcome of the trial was 28-day survival (20); we analyzed 28-day mortality (23) . To adjust for severity of illness, the predicted risk of mortality (PRM) was calculated from Acute Physiology and Chronic Health Evaluation (APACHE) III data (24, 25) . Plasma collected at screening prerandomization was frozen at -70°C. Plasma IL1RA and IL1β level were measured by enzyme-linked immunosorbent assay (ELISA) (R&D Systems) in duplicate for 20% of the population and singlet for the remainder due to low sample volume. The standard range for IL1RA was 39-5,000 pg/mL and for IL1β was 1.9-250 pg/mL. Laboratory personnel were blinded to clinical data including treatment status and survival.
Statistical analysis: subjects who received either dose of rhIL1RA were considered to have received rhIL1RA and were compared with those receiving placebo. Continuous variables were compared by the Wilcoxon rank sum test. Categorical variables were compared by chi-square testing. Correlation was assessed by Spearman statistics.
Our primary analysis was to test for heterogeneity in rhIL1RA treatment effect by baseline plasma biomarker concentrations, which would be indicated by a statistically significant interaction term. We followed a recommended framework to detect and report potential heterogeneity (26, 27) . We tested for rhIL1RA treatment effect heterogeneity by assessing the p-value of the interaction terms (rhIL1RA × biomarker decile) and (rhIL1RA × biomarker cut point dichotomization) in logistic regression of mortality upon APACHE III score, rhIL1RA treatment, and interaction defined above (26, 28) . We reasoned that treating plasma biomarker concentration by deciles would simulate continuous data and maximize information content, whereas dichotomizing the data would be easier to operationalize in a clinical setting as "biomarker positive" or "marker negative." The same approach was applied for IL1RA and IL1β concentration. We used a data-driven approach, the Youden method, to select the cut point in plasma concentration that best optimized the area under the mortality receiver operating characteristics curve (29, 30) . We also dichotomized the population according to median IL1RA and IL1β concentrations. We report the results of the Mantel-Haenszel test for inhomogeneity between stratum-specific odds ratios (31) . To ensure that the heterogeneity observed was a function of plasma level rather than potentially collinear severity of illness measures like the APACHE III score, we tested the interaction between rhIL1RA treatment and biomarker level across tertiles of predicted mortality, selecting tertiles given published examples (26) and because three levels of illness severity reconciled with clinical "high, low, intermediate" risk judgments. To display the interaction, we plotted Kaplan-Meier estimated survival for groups defined by baseline plasma IL1RA and rhIL1RA treatment.
When interaction was statistically significant (p < 0.05), we categorized patients into strata by biomarker cut point and used logistic regression accounting for APACHE III score to determine the association between rhIL1RA treatment with mortality. Following each stratum-specific logistic regression model, we used postestimation marginal analysis to convert odds ratios to risk differences by plasma marker concentration (32) , as this approach allows an estimation of the average treatment effect of rhIL1RA across all observations while holding other covariates at their original values. We used Stata Release 12 (College Station, TX) and considered a two-sided p-value less than 0.05 significant. We assumed a value of 0.1 pg/mL for subjects with undetectable plasma IL1β; plasma IL1RA was almost uniformly detectable. In sensitivity analyses, we excluded subjects with undetectable IL1β. As exploratory analyses, we tested for statistical interaction for the ratio of IL1RA to IL1β and the product IL1RA × IL1β. The online supplement (Supplemental Digital Content 1, http://links.lww.com/CCM/C895) presents additional analyses and further detail.
RESULTS
Characteristics of eligible patients who survived 28 days compared with those who died are shown in Table 1 , and patient flow is depicted in Figure 1 . Plasma was available for 59% of the original trial population. We had no information to explain why some subjects had available plasma and some did not. Subjects with plasma were similar to those who did not have plasma available (Table E1 , Supplemental Digital Content 1, http://links.lww.com/CCM/C895). The distribution of baseline characteristics among the 529 subjects with plasma was similar in the randomly assigned treatment groups ( (Table 1 ). In the overall population with plasma tested, similar to the reported trial results (20) , treatment with rhIL1RA was not significantly associated with mortality: adjusted risk difference (ARD) of -0.03 (95% CI, -0.09 to 0.04).
Our primary analysis was to test for potential heterogeneity in rhIL1RA treatment effect by plasma marker concentration. We performed logistic regression of 28-day mortality accounting for rhIL1RA treatment, APACHE III score, plasma IL1RA concentration (in deciles), and an interaction term (rhIL1RA treatment × plasma IL1RA decile). Both the APACHE III score (p < 0.001) and the interaction term between IL1RA decile and rhIL1RA treatment (p = 0.046) were associated with mortality. We used the Youden method to determine an empiric threshold of plasma IL1RA level associated with mortality and dichotomized the population by this value, a plasma IL1RA level of 2,071 pg/mL. We repeated the logistic regression including the interaction term (rhIL1RA treatment × plasma IL1RA cut point), and the interaction term remained significantly associated with mortality, p = 0.028. If we changed the cut point to the median plasma IL1RA concentration, the interaction term was also significant: p = 0.036. The significance of interaction terms was similar in models that excluded APACHE III score, and for log(IL1RA) treated continuously (p = 0.055).
Because there was potential collinearity between plasma IL1RA and severity of illness (Table 1; and Table E3 , Supplemental Digital Content 1, http://links.lww.com/CCM/ C895), we tested the interaction effect of plasma IL1RA level across tertiles (26) or deciles of APACHE III-PRM, and the interaction term remained statistically associated with mortality (p = 0.037 or p = 0.047, respectively). Having established a statistically significant interaction between plasma IL1RA concentration and rhIL1RA treatment effect, we undertook a stratified analysis of trial results by Youden-determined plasma IL1RA cut point. Applying the cut point, 286 subjects (54%) were characterized as being "plasma IL1RA high" and 243 (46%) as "plasma IL1RA low."
We performed stratum-specific logistic regression of mortality accounting for APACHE III score and rhIL1RA treatment ( Table 2) . Among subjects with plasma IL1RA below 2,071 pg/mL, rhIL1RA resulted in a nonsignificant increase in mortality, ARD 0.07 (95% CI, -0.04 to 0.17). In contrast, subjects with baseline IL1RA above 2,071 pg/mL demonstrated significantly reduced mortality with rhIL1RA, ARD ˗0.12 (95% CI, -0.23 to -0.01). A Mantel-Haenszel test determined the effect of rhIL1RA to be significantly inhomogeneous between these strata (p = 0.026). As shown in Table 3 , the treatment effect of rhIL1RA remained inhomogeneous by baseline plasma IL1RA concentration across different levels of predicted mortality, whereas no interaction was detected between rhIL1RA treatment and APACHE tertiles themselves. Figure 2 displays the interaction between rhIL1RA treatment and baseline plasma IL1RA, with a different direction of treatment effect depending on plasma IL1RA status. Results were unchanged when we used the median plasma IL1RA concentration to divide the population (Table E4 , Supplemental Digital Content 1, http://links. lww.com/CCM/C895). When we further stratified the analysis by rhIL1RA dose, there was no evidence for a dose-responsive aspect to the interaction, as shown in Table E5 (Supplemental Digital Content 1, http://links.lww.com/CCM/C895). Subjects with high plasma interleukin-1 receptor antagonist (IL1RA) had significantly reduced mortality when treated with rhIL1RA, whereas those with low baseline plasma IL1RA did not. Baseline plasma IL1RA was dichotomized at 2,071 pg/mL, the point at which the area under the receiver operator curve is maximized. Mantel-Haenszel test for inhomogeneity: p = 0.026. In a multivariable logistic regression model including Acute Physiology and Chronic Health Evaluation III score, rhIL1RA treatment, and the interaction term, the p value for the interaction term (rhIL1RA × plasma IL1RA cut point) was 0.028.
Analyses by IL1β level yielded no statistically significant interaction between plasma IL1β level and rhIL1RA treatment by IL1β decile (p = 0.24), Youden-determined IL1β cut point for mortality (p = 0.26), or by the median IL1β concentration (p = 0.49). Results were similar whether patients with undetectable plasma IL1β were included or excluded from the analyses ( 
DISCUSSION
We have demonstrated significant heterogeneity in the effect of rhIL1RA on sepsis mortality according to baseline plasma IL1RA concentration in a retrospective subgroup analysis of one randomized clinical trial. Subjects with low plasma IL1RA did not seem to benefit from rhIL1RA and may have incurred increased mortality, whereas subjects with higher baseline plasma IL1RA had approximately 12% mortality reduction when treated with rhIL1RA. Early plasma IL1RA level may act as an enrichment factor to select septic patients who may benefit from rhIL1RA therapy (4) .
It has long been recognized that a hyperimmune response to infection occurs in some patients with sepsis (34, 35) and that persistently elevated plasma levels of inflammatory cytokines strongly associate with death (36) . The plasma concentration of IL1β may be in the causal pathway toward septic shock and The raw mortality and adjusted risk difference of rhIL1RA treatment versus placebo is shown, stratified by APACHE III predicted mortality tertile and plasma IL1RA concentration. A consistent direction of effect was observed for rhIL1RA treatment for subjects with plasma IL1RA above 2,071 pg/mL across predicted mortality tertiles, whereas patients with low plasma IL1RA did not benefit. Maximal benefit was observed for patients with high APACHE III scores and elevated plasma IL1RA. The proportion of subjects with plasma IL1RA above the cut point 2,071 pg/mL increases from 45% among the lowest APACHE III tertile to 66% among the highest APACHE III tertile, as shown by the denominator in each cell. Whereas the interaction term (rhIL1RA × IL1RA cut point) remains statistically associated with adjusted mortality with a p value = 0.047, the interaction term (rhIL1RA × APACHE III tertile) was not significantly associated with adjusted mortality (p = 0.469). mortality (14, 17) . However, attempts to dramatically improve sepsis survival by blocking IL1β, although effective in animal models (37, 38) , repeatedly failed in human trials (19) (20) (21) . We hypothesized that subjects with an activated interleukin-1 axis would exhibit the largest beneficial treatment effect from rhIL1RA, yet were uncertain whether plasma IL1β or IL1RA would be the optimal marker (17, 18) . Although we did not detect a statistically significant interaction between rhIL1RA treatment and plasma IL1β, it is possible that, with a larger study, a more sensitive assay, and improved power, plasma IL1β would also function as an enrichment factor (39) ( Table  E5 ). An important but unanswered question is whether it may be harmful to suppress IL1β signaling in septic patients whose IL-1 axis is not activated. The interaction detected here suggests that rhIL1RA treatment had either no mortality effect or that the treatment worsened outcomes in the subgroup with low plasma IL1RA. The ambulatory use of rhIL1RA for nonseptic conditions is usually well tolerated, although severe infection and liver toxicity are rare but described complications (40) .
Although the drug appeared safe in three trials (19, 21, 23) , rhIL1RA treatment may contribute to sepsis-induced immune suppression (41, 42) . A hyperimmune response may occur concurrently with suppressed adaptive immunity during sepsis (43, 44) , and a hyperinflammatory state may contribute to subsequent T cell exhaustion or immunoparalysis. Overexpression of IL-1 pathway genes in whole blood during sepsis was associated with a higher likelihood of secondary delayed infection (45) , potentially linking IL-1 dysfunction and hypoimmunity. Future attempts to replicate a benefit of rhIL1RA should interrogate markers of adaptive immune exhaustion at baseline and with treatment (46) . During sepsis, plasma IL1RA exists in quantities often in excess of 1,000-fold higher than plasma IL1β (47) , and it is counterintuitive that subjects with high plasma IL1RA were those who benefitted from exogenous rhIL1RA (48) . Our findings are somewhat contrary to our prior report that subjects with a genetic variant showing more efficient IL1RN expression had a lower sepsis mortality (18) . We hypothesize that plasma IL1RA and IL1β are more strongly correlated as sepsis persists (18, 47) , and since IL1β induces gene expression of both itself and the gene encoding IL1RA (15, 49) , early abundant IL1RA expression may dampen IL1β, stopping the cycle of IL1β-IL1RA amplification. We posit that a high circulating plasma IL1RA concentration is an indicator that IL1B is transcriptionally active. Conversely, when septic patients do not mount a plasma IL1RA response, this may indicate that IL-1 pathway activation is not a major contributor to the patient's condition. However, prospective clinical trials with carefully timed plasma collection are necessary to answer this question directly.
The significant interaction we detected between rhIL1RA treatment and baseline plasma IL1RA concentration was present across multiple levels of predicted mortality (26) . Because patients with higher severity of illness have a higher mortality event rate, this group will be better powered to detect a treatment effect. The APACHE III score thus functions as a prognostic biomarker for rhIL1RA response (4, 23) . The value of high plasma IL1RA as a biomarker may likewise select a more sick population, for prognostic enrichment, or it may be that high plasma IL1RA provides information about a patient's likely response to rhIL1RA as a predictive biomarker (4). Biomarker-enriched clinical trials can benefit from both prognostic and predictive enrichment (4), and as evident in Table 3 , it may be that the optimal design for a future trial of rhIL1RA in sepsis would require both a high APACHE III and an elevated plasma IL1RA for eligibility.
Our study had important limitations. We were limited in the number of subjects available with plasma, the plasma quantity available, and the clinical information stored in the permanently deidentified database. We evaluated slightly less than 60% of the original trial population, which risks selection bias; the behavior of plasma IL1RA in subjects without stored plasma is unknown. Although neither phase III trial of rhIL1RA in sepsis detected a significant beneficial effect (20, 21) , the subpopulation analyzed here was drawn from the 1994 trial, which had more signal for benefit, and it is thus possible that subgroup analyses would favor benefit in this trial but not the 1997 trial. Unfortunately, samples from the 1997 trial (21) do not exist. We assayed plasma proteins on plasma stored for over 20 years. There is precedent for reporting plasma IL1RA and IL1β on samples stored greater than 15 years (50), and these proteins are stable through multiple freeze/thaw cycles (51); however, many questions remain regarding the kinetics of these proteins during sepsis. However, these limitations apply equally to all samples and any degradation would be expected to bias our findings toward the null hypothesis.
We derived a plasma IL1RA threshold with optimal operating characteristics (≥ 2,071 pg/mL); however, this threshold may not have inherent value because a cut point is always best fit to its discovery population. Furthermore, although the observed coefficient of variation for these assays was not excessive (7%), our lack of duplicates for a majority of samples may decrease the precision of the threshold. In addition, temporal changes in sepsis and supportive care, including ventilation, are likely to have impacted the observed range of plasma IL1β and IL1RA (52) . The values observed here were between 3-and 10-fold higher than those reported in a 2008 sepsis trial (17, 18) . For these multiple reasons, we advocate an independent trial to validate thresholds of IL1RA in a modern sample as a necessary precursor to a new precision trial.
We tested two primary and two exploratory biomarkers (IL1RA, IL1β, IL1RA/IL1β, and IL1RA × IL1β) and did not adjust for multiple comparisons because having demonstrated moderate to strong correlation between IL1RA and IL1β during sepsis (17, 18, 53) , we did not consider these tests independent. With an alpha level of 0.05 and four tests, no marker would be expected to show significant interaction by chance; however, our interaction testing would not be robust to a Bonferroni adjustment (27) . In our secondary analysis, we report significance testing for subgroups (Table 2) without multiple comparison adjustment. Subgroup analyses have reduced statistical power, increased variance, and a high rate
